AtaiBeckley doses last patient in Elumina, phase 2b trial of VLS-01 in adults with treatment-resistant depression: New York Tuesday, July 7, 2026, 10:00 Hrs [IST] AtaiBeckley Inc.
This cell-like structure can grow, feed, divide and compete. Researchers ponder what it means for the future of synthetic ...
Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...
Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...
Ten years ago, a franchisee reached out for help. His business was failing, and he couldn't find guidance on how to save his dream. So, Aicha Bascaro ? a former pizza delivery driver turned global ...
The airwaves are crackling this week with news of the first synthetic cell, constructed and cultured by researchers from the ...
Plus inc. today announced that John Lutz, a senior executive with more than 30 years' experience across global technology and institutional environments, has joined its Board of ...
The University of Minnesota scientist speaks to Times Now Digital about SpudCell, the synthetic cell that can grow and ...
The US administration’s crackdown on tax breaks being exploited by start-up investors is a warning for Jim Chalmers about the ...
Agro Spectrum India on MSN
Asia’s gene-editing revolution faces its next political test
India’s landmark release of the world’s first genome-edited rice and China’s rapid regulatory approvals signal a new era for ...
Chandigarh Enterprise and Investment Bureau to be established to function as the nodal agency for facilitating investment ...
Healthcare veteran Dr Douglas Williams discusses the impact of recent political upheaval in the US and the prospect of major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results